Abstract
A randomized phase III study was carried out in 57 patients with metastatic melanoma treated with either dacarbazine (DTIC) given intravenously (IV) daily for 10 days using light protection, or a combination of vinblastine IV on days 1 and 2, bleomycin by continuous IV infusion during days 1-5, and cisplatin by IV infusion on day 5 (VBD). Objective response rates were similar: 14% for dacarbazine and 10% for VBD. However, dacarbazine responses were associated with a trend toward longer progression-free intervals and longer survival. Toxicity was significantly greater in the VBD arm, and fatal in two patients. Dacarbazine was also associated with severe toxicity by the 10-day light-protected schedule used here. VBD is not as effective as previously reported, and dacarbazine remains a standard of therapy for metastatic melanoma.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Clinical Trials as Topic
-
Dacarbazine / administration & dosage*
-
Dacarbazine / adverse effects
-
Female
-
Humans
-
Male
-
Melanoma / drug therapy*
-
Melanoma / mortality
-
Middle Aged
-
Mouth Diseases / chemically induced
-
Neutropenia / chemically induced
-
Random Allocation
-
Sepsis / chemically induced
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / mortality
-
Thrombocytopenia / chemically induced
-
Vinblastine / administration & dosage
-
Vinblastine / adverse effects
Substances
-
Bleomycin
-
Vinblastine
-
Dacarbazine
-
Cisplatin